**Result**:
- Number:
    - Indacaterol+tiotropium: 572
    - Placebo+tiotropium: 570
- Differences between indacaterol+tio vs. tio+placebo
    - FEV1 AUC 5 min~8 h:
        - COPD severity - moderate: 130 mL (90~160)
        - - severe: 110 mL (80~140)
        - Smoking status - ex smoker: 140 mL (110~170)
        - - current smoker: 90 mL (50~120)
        - ICS use - non-users: 140 mL (100~170)
        - - users: 100 mL (70~140)
- Trough FEV1:
    - COPD severity:
        - moderate: Indacaterol+tiotropium: 90 mL (60~120), Placebo+tiotropium: 60 mL (20~90)
        - severe: Indacaterol+tiotropium: 60 mL (30~90), Placebo+tiotropium: 60 mL (30~90)
    - Smoking status:
        - ex smoker: Indacaterol+tiotropium: 80 mL (60~110), Placebo+tiotropium:
        - current smoker: Indacaterol+tiotropium: 60 mL (20~90), Placebo+tiotropium:
    - ICS use:
        - non-users: Indacaterol+tiotropium: 90 mL (60~120), Placebo+tiotropium:
        - users: Indacaterol+tiotropium: 60 mL (30~90), Placebo+tiotropium:
- Patient reported symptoms and use of as-needed salbutamol:
    - Change from baseline symptom score (full 24 h): Indacaterol+tiotropium: -2,2 (0,21), Placebo+tiotropium: -1,5 (0,21)
    - Change from baseline symptom score (day-time): Indacaterol+tiotropium: -1,1 (0,12), Placebo+tiotropium: -0,8 (0,12)
    - Change from baseline symptom score (night-time): Indacaterol+tiotropium: -1,0 (0,12), Placebo+tiotropium: -0,7 (0,12)
    - Change from baseline salbutamol use (puff/day): Indacaterol+tiotropium: -2,1 (0,17), Placebo+tiotropium: -1,4 (0,17)
    - Days during treatment with no salbutamol use (%): Indacaterol+tiotropium: 38,7 (1,94), Placebo+tiotropium: 33,6 (1,92)
- Adverse events (%):
    - Cough: Indacaterol+tiotropium: 9,1, Placebo+tiotropium: 4,4
    - Muscle spasm: Indacaterol+tiotropium: 0,3, Placebo+tiotropium: 1,1
    - Plasma potassium <3,5 mmol/L: Indacaterol+tiotropium: 1,6, Placebo+tiotropium: 1,4
    - Systolic BP-high: Indacaterol+tiotropium: 0,7, Placebo+tiotropium: 0,4
    - QTc interval (absolute value): Indacaterol+tiotropium: 1,8, Placebo+tiotropium: 2,6

\*post-salbutamol for FEV1 % and FEV1/FVC and pre/post salbutamol for reversibility

PICO 및 근거표

## 6) 폐기능이 정상예측치의 60%인 미만인 경우 증상 호전, 폐기능과 삶의 질 향상, 급성 악화 감소를 위해 흡입스테로이드 사용을 추가할 수 있다(근거수준: 낮음, 권고강도: 강함).

### 근거표 6; Inhaled corticosteroid

| 연구수 | 연구설계 | 비뚤림 위험 | 비일관성 | 비직접성 | 비정밀 | 출판 비뚤림 | 근거수준 |
|---|---|---|---|---|---|---|---|
| 1 | 사후분석 | 없음 | 없음 | 없음 | 없음 | 없음 | 낮음 |

Author/year publication: Multicenter, Christine R Jenkins
Title: Efficacy of salmeterol/fluticasone propionate by GOLD stage of COPD; analysis from the randomized, placebo-controlled TORCH study
Country: 42 countries including Australia, London, USA, and Denmark
Setting/Design: Double-blind, placebo-controlled trial
Time frame: 2 Year (September 2000 and the last in November 2002)
Randomization method: Permuted blocks with stratification according to country and smoking status
Allocation concealment: Yes
Blinding:
- Participants: Yes

<PAGE>110